Universal Beteiligungs und Servicegesellschaft mbH Sells 22,256 Shares of Innoviva, Inc. $INVA

Universal Beteiligungs und Servicegesellschaft mbH lowered its holdings in Innoviva, Inc. (NASDAQ:INVA) by 64.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,303 shares of the biotechnology company’s stock after selling 22,256 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Innoviva were worth $247,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Parallel Advisors LLC increased its position in shares of Innoviva by 157.5% during the 2nd quarter. Parallel Advisors LLC now owns 1,849 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,131 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Innoviva in the 1st quarter worth about $56,000. Hantz Financial Services Inc. grew its position in Innoviva by 4,715.6% during the second quarter. Hantz Financial Services Inc. now owns 4,623 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 4,527 shares during the period. GAMMA Investing LLC grew its position in Innoviva by 58.9% during the second quarter. GAMMA Investing LLC now owns 7,146 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 2,648 shares during the period. Finally, US Bancorp DE increased its holdings in Innoviva by 356.0% during the first quarter. US Bancorp DE now owns 12,753 shares of the biotechnology company’s stock worth $231,000 after buying an additional 9,956 shares during the last quarter. Institutional investors own 99.12% of the company’s stock.

Innoviva Stock Up 0.2%

Innoviva stock opened at $21.75 on Friday. The firm has a 50 day simple moving average of $19.13 and a 200 day simple moving average of $19.57. The company has a current ratio of 2.64, a quick ratio of 2.44 and a debt-to-equity ratio of 0.36. Innoviva, Inc. has a 1-year low of $16.52 and a 1-year high of $22.76. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of 70.17 and a beta of 0.42.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.62. The firm had revenue of $107.80 million during the quarter, compared to analyst estimates of $91.31 million. Innoviva had a return on equity of 18.67% and a net margin of 10.44%. On average, analysts predict that Innoviva, Inc. will post 0.33 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on INVA. Weiss Ratings reiterated a “buy (b-)” rating on shares of Innoviva in a research note on Tuesday. Zacks Research cut shares of Innoviva from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. HC Wainwright upped their price objective on Innoviva from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, August 11th. Cantor Fitzgerald increased their price objective on Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, The Goldman Sachs Group began coverage on Innoviva in a research report on Tuesday, September 30th. They issued a “sell” rating and a $17.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Innoviva presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.60.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.